47 results on '"Strand V"'
Search Results
2. The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
3. POSA96 The Economic Burden of Thromboembolic Events (TE) Among Patients with Inflammatory Bowel Disease (IBD)
4. PMU8 The Economic Burden of Thromboembolic Events Among Patients with Immune-Mediated Diseases
5. Comparison of intra-articular sham and vehicle injection from a phase 2b trial of SM04690, a small-molecule Wnt inhibitor, for knee osteoarthritis
6. Abstract # 3081 Impaired cognition and fatigue; the role of sleep and neuroinflammation for non-specific symptoms in allergy
7. Secukinumab Shows Higher Symptomatic improvement Versus Infliximab in Psoriatic Arthritis: Comparative Effectiveness Up To 1 Year Assessed by Matching-Adjusted Indirect Comparisons
8. Appropriate Psoriatic Arthritis Treatment is Delayed for Years: Results From a Multi-National Survey Including Latin America
9. Delayed Biologic Switching Among Ankylosing Spondylitis (As) Patients May Result in Poor Health- Related Quality of Life: Results From A Multi-National Survey Including Latin America
10. Appropriate Ankylosing Spondylitis (AS) Treatment is Delayed For Years: Results From a Multi-National Survey Including Latin America
11. Ankylosing Spondylitis Limits Patients’ Ability to Contribute to Society As Part of the Workforce: Results from A Multi-National Survey Including Latin America
12. Delayed Biologic Switching Among Psoriatic Arthritis (Psa) Patients May Result in Poor Health-Related Quality of Life: Results From A Multi-National Survey Including Latin America
13. Psoriatic Arthritis Limits Patients’ Ability to Contribute to Society As Part of the Workforce: Results from A Multi-National Survey Including Latin America
14. An intra-articular, extended release formulation of triamcinolone (FX006) affords clinically relevant improvements in pain and function of knee osteoarthritis: post-hoc pooled analyses of 3 randomized controlled trials
15. 054 Treatment with ixekizumab over 60 weeks provides sustained improvements in health-related quality of life: Results from UNCOVER-1, a randomized phase 3 trial
16. OMERACT-OARSI ‘strict responders’ analysis from results of a randomized, double-blind, placebo-controlled phase 1 study of a novel, intra-articular, injectable, Wnt inhibitor (SM04690) in the treatment of osteoarthritis of the knee
17. A Real-World Characterization of Patients With “Moderate-To-Severe” Systemic Lupus Erythematosus
18. Work Productivity Improvement Associated With Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis Results Of A Phase 3, Randomized, Controlled Trial
19. Sustained Improvements In Health-Related Quality Of Life In Patients With Systemic Lupus Erythematosus Following Epratuzumab TreatmentResults From A Phase Iib Study And Its Open-Label Extension
20. Burden Of Disease In Systemic Lupus Erythematosus Patients Treated With Corticosteroids
21. Effect Of Certolizumab Pegol On Workplace And Household Productivity In United States Patients With Rheumatoid Arthritis With Or Without Prior Anti-Tnf Exposure: Results From The Predict Study
22. A phase 3 randomized controlled trial of lower-dose diclofenac capsules in patients with osteoarthritis pain: impact on patient-reported outcomes
23. Expanding the Measurement of Treatment Benefit in Rheumatoid Arthritis: The Role of the Patient-Reported Outcome Consortium’s RA Working Group
24. Long-Term Benefits Over More Than 4 Years of Certolizumab Pegol Combination Therapy on Workplace and Household Productivity, and Participation in Social Activities in Rheumatoid Arthritis: Results from the Open-Label Extension Study of Rapid1
25. PHS68 An Assessment of Impairment of Productivity Among SLE Patients
26. PMS67 Long-Term Benefits of 4-Weekly Certolizumab Pegol Combination and Monotherapy on Household Productivity and Social Participation in Rheumatoid Arthritis: 5 Year Results from an Open Label Extension Study
27. PMS72 Evaluation of Clinical Performance and Variation among Three Types of Patients with Rheumatoid Arthritis: Opportunities to Raise Quality and Lower Costs
28. A multicenter, randomized controlled trial comparing a single intra-articular injection of Gel-200, a new cross-linked formulation of hyaluronic acid, to phosphate buffered saline for treatment of osteoarthritis of the knee
29. Safety and efficacy profile of nano-formulated, lower dose non-steroidal anti-inflammatory drugs
30. Amélioration de la fatigue et la qualité de vie à 52 semaines chez les patients atteints de lupus systémique répondeurs dans les essais cliniques de phase 3 du bélimumab
31. PMS62 Improved Fatigue and Physical Function are Correlated with Health-Related Quality of Life in Psoriatic Arthritis Subjects Treated with Apremilast: Results from a Phase 2, Randomized, Controlled Study
32. PSY36 DEVELOPMENT OF THE LUPUS IMPACT TRACKER: A TOOL FOR PATIENTS AND PHYSICIANS TO ASSESS AND MONITOR THE IMPACT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
33. Safety issues in the development of treatments for osteoarthritis: recommendations of the Safety Considerations Working Group
34. PSY35 VALIDATION OF THE LUPUS IMPACT TRACKER
35. PMS4 NUMBER NEEDED TO TREAT FOR PATIENTS TO REPORT BROAD RELIEF FROM THE BURDEN OF RHEUMATOID ARTHRITIS WHEN TREATED WITH CERTOLIZUMAB PEGOL PLUS METHOTREXATE
36. PMS62 CERTOLIZUMAB PEGOL MONOTHERAPY PROVIDES SUSTAINED IMPROVEMENTS IN HOUSEHOLD PRODUCTIVITY AND DAILY ACTIVITIES IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS OVER 2 YEARS
37. PMS84 IMPACT OF CERTOLIZUMAB PEGOL (CZP) ON HEALTH-RELATED QUALITY OF LIFE (HRQOL): RHEUMATOID ARTHRITIS (RA) PATIENTS APPROACH POPULATION US NORMS IN MENTAL HEALTH AND VITALITY DOMAINS
38. PMS11 PERCEPTIONS OF TREATMENT OUTCOMES AMONG NEW USERS OF TNF ANTAGONISTS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
39. 341 DURATION OF A SINGLE INTRAARTICULAR INJECTION OF GEL-200 AND SAFETY OF RE-TREATMENT OF GEL-200, A NEW CROSS-LINKED FORMULATION OF HYALURONIC ACID [HA] IN THE TREATMENT OF SYMPTOMATIC OSTEOARTHRITIS [OA] OF THE KNEE
40. 326 EFFECTIVENESS AND SAFETY OF A SINGLE INTRAARTICULAR INJECTION OF GEL-200, A NEW CROSS-LINKED FORMULATION OF HYALURONIC ACID [HA] IN THE TREATMENT OF SYMPTOMATIC OSTEOARTHRITIS [OA] OF THE KNEE
41. Changes in patient global impression of hange ratings are associated with pain and other symptoms in two milnacipran clinical trials in fibromyalgia
42. Milnacipran improves health-related quality of life in patients with fibromyalgia (FM): results from a pivotal phase III randomized controlled trial
43. An integrated analysis of five double-blind, randomized controlled trials evaluating the safety and efficacy of a hyaluronan product for intra-articular injection in osteoarthritis of the knee
44. PES17 IMPROVED HEALTH-RELATED QUALITY OF LIFE FOLLOWING SUSTAINED REDUCTIONS IN ANTI DS-DNA ANTIBODYS [ÁDSDNA AB] IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AFTER TREATMENT WITH LJP394
45. OMERACT-OARSI Initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited.
46. Ambient level of NO2 augments the inflammatory response to inhaled allergen in asthmatics
47. PAM14: TREATMENT WITH LEFLUNOMIDE IMPROVES THE UTILITY OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: AN APPLICATION OF THE SF-6D
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.